Western Blot (WB)
(Figure 1 Western Blot Validation of BACELoading: 15 ug of lysates per lane. Antibodies: BACE (1ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane A-C: human brain tis)
Rabbit anti-Human, Mouse BACE Polyclonal Antibody | anti-BACE1 antibody
BACE Antibody
IHC-P: 2.5 ug/mL
ICC: 10 ug/mL
IF: 20 ug/mL.
Antibody validated: Western Blot in human and mouse samples; Immunohistochemistry, Immunocytochemistry and Immunofluorescence in mouse samples. All other applications and species not yet tested.
The immunogen is located within the last 50 amino acids of BACE.
KO validation (Figure 6,9): Anti-BACE antibody (MBS150291) specificity was further verified by BACE KO mice (figure6) and KO cell line (figure9). BACE signal was not detected in BACE KO mice and KO cell line.
KD validation (Figure 7,8,10): Anti-BACE antibody (MBS150291) specificity was verified by BACE specific siRNA knockdown. BACE signal in mouse brain injected with BACE siRNAs and DRG transfected with BACE siRNAs was disrupted in comparison with control.
Overexpression validation (Figure 6): Anti-BACE antibody (MBS150291) detected high expression levels of BACE in 293 cells transfected with hBACE or mBACE (figure6) as compared to eGFP transfected cells.
Western Blot (WB)
(Figure 1 Western Blot Validation of BACELoading: 15 ug of lysates per lane. Antibodies: BACE (1ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane A-C: human brain tis)
Western Blot (WB)
(Figure 1 Western Blot Validation of BACELoading: 15 ug of lysates per lane. Antibodies: BACE (1ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane A-C: human brain tis)
Western Blot (WB)
(Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell LinesLoading: 15 μg of lysates per lane.Antibodies: BACE (MBS150291) (1 μg/mL), BACE ProMab (1 μg/mL), beta-actin (1 μg/mL), and GAPDH (0.02 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.)
Western Blot (WB)
(Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell LinesLoading: 15 μg of lysates per lane.Antibodies: BACE (MBS150291) (1 μg/mL), BACE ProMab (1 μg/mL), beta-actin (1 μg/mL), and GAPDH (0.02 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.)
Immunohistochemistry (IHC)
(Figure 3 Immunohistochemistry Validation of BACE in Mouse Brain Immunohistochemical analysis of paraffin-embedded mouse brain tissue using anti-BACE antibody (MBS150291) at 2.5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4?C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.)
Immunohistochemistry (IHC)
(Figure 3 Immunohistochemistry Validation of BACE in Mouse Brain Immunohistochemical analysis of paraffin-embedded mouse brain tissue using anti-BACE antibody (MBS150291) at 2.5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4?C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.)
Immunofluorescence (IF)
(Figure 4 Immunofluorescence Validation of BACE in 3T3/NIH CellsImmunofluorescent analysis of 4% paraformaldehydefixed mouse 3T3/NIH cells labeling BACE with MBS150291 at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue). Image showing both membrane and cytosol staining on 3T3/NIH cells.)
Immunofluorescence (IF)
(Figure 4 Immunofluorescence Validation of BACE in 3T3/NIH CellsImmunofluorescent analysis of 4% paraformaldehydefixed mouse 3T3/NIH cells labeling BACE with MBS150291 at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue). Image showing both membrane and cytosol staining on 3T3/NIH cells.)
Immunocytochemistry (IHC)
(Figure 5 Immunocytochemistry Validation of BACE in 3T3/NIH CellsImmunohistochemical analysis of 3T3/NIH cells using anti-BACE antibody (MBS150291) at 10 μg/ml. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.)
Immunocytochemistry (IHC)
(Figure 5 Immunocytochemistry Validation of BACE in 3T3/NIH CellsImmunohistochemical analysis of 3T3/NIH cells using anti-BACE antibody (MBS150291) at 10 μg/ml. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.)
Western Blot (WB)
(Figure 6 KO and Overexpression Validation of BACE in Human and Mouse Brain and 293 Cells. (Singer et al., 2005)Western blot analysis of the BACE1 (MBS150291) antibody’s ability to recognize human and murine BACE1. The BACE1 antibody recognized both the mouse and human forms of BACE1. Lanes 1–4 are frontal cortex homogenates from human and mouse brains. Lane 1 is from a neurologically unimpaired aged human control case, lane 2 from a BACE1-deficient mouse, lane 3 from a nontransgenic mouse and lane 4 from hBACE1 transgenic mouse. Lanes 5–7 are lysates from HEK293T cells transfected with a plasmid vector expressing eGFP, mBACE1 and hBACE1, respectively.)
Western Blot (WB)
(Figure 6 KO and Overexpression Validation of BACE in Human and Mouse Brain and 293 Cells. (Singer et al., 2005)Western blot analysis of the BACE1 (MBS150291) antibody’s ability to recognize human and murine BACE1. The BACE1 antibody recognized both the mouse and human forms of BACE1. Lanes 1–4 are frontal cortex homogenates from human and mouse brains. Lane 1 is from a neurologically unimpaired aged human control case, lane 2 from a BACE1-deficient mouse, lane 3 from a nontransgenic mouse and lane 4 from hBACE1 transgenic mouse. Lanes 5–7 are lysates from HEK293T cells transfected with a plasmid vector expressing eGFP, mBACE1 and hBACE1, respectively.)
Immunohistochemistry (IHC)
(Figure 7 KD Validation of BACE in Mouse Brain (Singer et al., 2005)Characterization of the effects of lenti-siBACE1-6 expression in the brains of APP transgenic mice. (a–d) Anti-eGFP immunoreactivity in the hippocampus (the injection site) shows comparable and consistent expression of lenti-siRNA constructs in the dentate gyrus (dg) and stratus polymorphus (sp). (e) Anti-BACE1 immunoreactivity in the hippocampus of nontransgenic mice treated with lenti-siGlut4. (f) Reduced BACE1 immunostaining in the hippocampus of nontransgenic mice treated with lenti-siBACE1-6 vector. (g) Intense BACE1 immunoreactivity in the hippocampus of APP transgenic mice treated with lenti-siGlut4. (h) Reduced BACE1 expression in APP transgenic mice treated with lenti-siBACE1-6 vector. (i,j) Anti-BACE1 reacted with pyramidal cell bodies in the neocortex, which was not injected,)
Immunohistochemistry (IHC)
(Figure 7 KD Validation of BACE in Mouse Brain (Singer et al., 2005)Characterization of the effects of lenti-siBACE1-6 expression in the brains of APP transgenic mice. (a–d) Anti-eGFP immunoreactivity in the hippocampus (the injection site) shows comparable and consistent expression of lenti-siRNA constructs in the dentate gyrus (dg) and stratus polymorphus (sp). (e) Anti-BACE1 immunoreactivity in the hippocampus of nontransgenic mice treated with lenti-siGlut4. (f) Reduced BACE1 immunostaining in the hippocampus of nontransgenic mice treated with lenti-siBACE1-6 vector. (g) Intense BACE1 immunoreactivity in the hippocampus of APP transgenic mice treated with lenti-siGlut4. (h) Reduced BACE1 expression in APP transgenic mice treated with lenti-siBACE1-6 vector. (i,j) Anti-BACE1 reacted with pyramidal cell bodies in the neocortex, which was not injected,)
Immunofluorescence (IF)
(Figure 8 KD Validation of BACE in Mouse Brain (Singer et al., 2005)Immunolabeling patterns of BACE1 expression and the lenti-siRNA distribution. Sections from APP transgenic mice treated with the eGFPtagged lenti siRNA vectors (green) were co-immunolabeled with an antibody against BACE1 (red) and imaged with the LSCM. All sections are from the hippocampus of treated mice. (a–c) Lenti-siBACE1-6–treated mice. Areas within the hippocampus expressing the eGFP tagged vector have reduced BACE1 immunolabeling. (d–f) Mice treated with the eGFP-tagged control lenti-siGlut4 show unchanged expression of BACE1 in the hippocampus. (g–i) Mice treated with a saline vehicle show unchanged expression of BACE1 in the hippocampus..)
Immunofluorescence (IF)
(Figure 8 KD Validation of BACE in Mouse Brain (Singer et al., 2005)Immunolabeling patterns of BACE1 expression and the lenti-siRNA distribution. Sections from APP transgenic mice treated with the eGFPtagged lenti siRNA vectors (green) were co-immunolabeled with an antibody against BACE1 (red) and imaged with the LSCM. All sections are from the hippocampus of treated mice. (a–c) Lenti-siBACE1-6–treated mice. Areas within the hippocampus expressing the eGFP tagged vector have reduced BACE1 immunolabeling. (d–f) Mice treated with the eGFP-tagged control lenti-siGlut4 show unchanged expression of BACE1 in the hippocampus. (g–i) Mice treated with a saline vehicle show unchanged expression of BACE1 in the hippocampus..)
Western Blot (WB)
(Figure 9 KO Validation of BACE in MEF Cells (Jo et al., 2010)Wildtype and BACE -/- MEFs were exposed to HNE (15_M) for 2 h. BACE1 levels were examined by Western blot with anti-BACe antibodies (MBS150291).)
Western Blot (WB)
(Figure 9 KO Validation of BACE in MEF Cells (Jo et al., 2010)Wildtype and BACE -/- MEFs were exposed to HNE (15_M) for 2 h. BACE1 levels were examined by Western blot with anti-BACe antibodies (MBS150291).)
Immunofluorescence (IF)
(Figure 10 KD Validation of BACE in DRG (Hyun, 2007)Decreased BACE1 expression in DRG following siRNA3 transfection. DRG neurons were transfected with 1 ug siRNA3 plasmid and incubated for 48 hours in 37°˚C. DRG neurons were stained for BACE1 us¬ing the Anti-BACE antibody (a,b) Neurons transfected with the control plas¬mid pSUPER-EGFP (green) did not display any changes in BACE1 expression (red). (c,d) DRG neurons transfected with siR¬NA3 displayed reduced BACE1 expression in the axon.)
Immunofluorescence (IF)
(Figure 10 KD Validation of BACE in DRG (Hyun, 2007)Decreased BACE1 expression in DRG following siRNA3 transfection. DRG neurons were transfected with 1 ug siRNA3 plasmid and incubated for 48 hours in 37°˚C. DRG neurons were stained for BACE1 us¬ing the Anti-BACE antibody (a,b) Neurons transfected with the control plas¬mid pSUPER-EGFP (green) did not display any changes in BACE1 expression (red). (c,d) DRG neurons transfected with siR¬NA3 displayed reduced BACE1 expression in the axon.)
NCBI and Uniprot Product Information
Observed: 65kD (Post-modification: 4 N-linked glycosylation)
NCBI Description
Cerebral deposition of amyloid beta peptide is an early and critical feature of Alzheimer's disease. Amyloid beta peptide is generated by proteolytic cleavage of amyloid precursor protein (APP) by two proteases, one of which is the protein encoded by this gene. The encoded protein, a member of the peptidase A1 protein family, is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. Multiple transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, May 2011]
Uniprot Description
BACE: an integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. Cleaves APP at the amino terminus of the A-beta peptide sequence, leading to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated carboxy-terminal fragment which is later release by gamma-secretase. Four splice-variant isoforms have been described.
Protein type: Protease; Membrane protein, integral; EC 3.4.23.46
Chromosomal Location of Human Ortholog: 11q23.2-q23.3
Cellular Component: Golgi apparatus; multivesicular body; cytoplasmic vesicle membrane; cell surface; axon; endoplasmic reticulum; integral to plasma membrane; late endosome; integral to membrane; plasma membrane; trans-Golgi network; endosome
Molecular Function: protein binding; enzyme binding; beta-amyloid binding; beta-aspartyl-peptidase activity; aspartic-type endopeptidase activity
Biological Process: beta-amyloid metabolic process; membrane protein ectodomain proteolysis; proteolysis
Research Articles on BACE1
Similar Products
Product Notes
The BACE1 bace1 (Catalog #AAA150291) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The BACE Antibody reacts with Human, Mouse and may cross-react with other species as described in the data sheet. AAA Biotech's BACE can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Immunocytochemistry (ICC), Immunofluorescence (IF), Immunohistochemistry (IHC-P), Western Blot (WB). WB: 1 ug/mL IHC-P: 2.5 ug/mL ICC: 10 ug/mL IF: 20 ug/mL. Antibody validated: Western Blot in human and mouse samples; Immunohistochemistry, Immunocytochemistry and Immunofluorescence in mouse samples. All other applications and species not yet tested. Researchers should empirically determine the suitability of the BACE1 bace1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "BACE, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
